HALD SR 400 MG

Top Selling, Women Health

Description
Shipping Options
Customer Reviews

HALD SR 400 mg is a high-dose, long-acting intramuscular (IM) depot injection of haloperidol decanoate, designed for maintenance therapy in severe, chronic psychotic disorders (e.g., treatment-resistant schizophrenia) in patients with significant compliance issues.

Composition

Active Ingredient: Haloperidol Decanoate 400 mg/mL (in sesame oil base).
Vehicle: Sesame oil, benzyl alcohol (preservative).

Mechanism of Action

Potent dopamine (D₂) receptor antagonist (primary action in mesolimbic pathway).
Also blocks serotonin (5-HT₂), alpha-1 adrenergic, and histamine (H₁) receptors.
Slow-release formulation: Provides sustained antipsychotic effects for 4 weeks per dose.

Dosage & Administration

Initial Dose (for Stabilized Patients)

Only for patients already stabilized on lower doses (e.g., 200–300 mg monthly).
Max initial dose: 300 mg IM (400 mg is not for first-time depot users).

Maintenance Dose

200–400 mg IM every 4 weeks (reserved for severe cases with proven tolerance).

Administration

Deep IM injection (gluteal muscle preferred).
Never give IV or subcutaneously (risk of oil embolism).

Switching from Oral to Depot

Overlap oral haloperidol for 4–8 weeks to ensure stability before using 400 mg dose.

Indications

✅ Severe, treatment-resistant schizophrenia (non-adherent patients). ✅ Chronic psychotic disorders with high relapse risk. ❌ Not for acute psychosis or first-episode patients.

Storage & Stability

Store at 15–30°C, protect from light.
Do not freeze (oil base may solidify).
Stable for 3 months after first use if stored properly.

Key Recommendations

✔ Strictly monitor for EPS (high risk of dystonia, akathisia, tardive dyskinesia). ✔ Mandatory ECG monitoring (↑↑ QT prolongation risk at this dose). ✔ Avoid in elderly/dementia patients (↑ mortality – Black Box Warning). ✔ Titrate slowly (400 mg is only for patients tolerating 300 mg well).

Important Safety Notes

⚠ Black Box Warnings:

↑ Mortality in elderly dementia patients (not approved for dementia-related psychosis).
High risk of QT prolongation & torsades de pointes.

⚠ Contraindications:

Parkinson’s disease/Lewy body dementia (worsens motor symptoms).
Congenital long QT syndrome.
Severe hepatic impairment.

⚠ Pregnancy (Category C): Risk of neonatal EPS; avoid unless critical.

Adverse Effects

Common	Serious
– Severe EPS (dystonia, tremors)	– Neuroleptic malignant syndrome (NMS)
– Sedation	– Torsades de pointes
– Weight gain	– Irreversible tardive dyskinesia
– Hyperprolactinemia	– Seizures

Drug Interactions

Interacting Drug	Effect	Management
CYP3A4 inhibitors (ketoconazole)	↑↑ Haloperidol levels	Contraindicated
QT-prolonging drugs (amiodarone)	↑↑ Arrhythmia risk	Absolute avoid
CNS depressants (benzodiazepines)	↑↑ Sedation	Extreme caution

Comparison with Other High-Potency Depot Antipsychotics

Feature	HALD SR 400 mg	Fluphenazine Decanoate	Zuclopenthixol Decanoate
Dosing Interval	Every 4 weeks	Every 2–4 weeks	Every 2–4 weeks
EPS Risk	Very High	High	Moderate-High
QT Risk	Extreme	High	Moderate
Cost	Low	Low	Moderate

Conclusion

HALD SR 400 mg is a high-risk, high-potency depot antipsychotic reserved for the most severe, treatment-resistant cases. Close monitoring for cardiac and neurological effects is mandatory.

Composition

Active Ingredient: Haloperidol Decanoate 400 mg/mL (in sesame oil base).
Vehicle: Sesame oil, benzyl alcohol (preservative).

Mechanism of Action

Potent dopamine (D₂) receptor antagonist (primary action in mesolimbic pathway).
Also blocks serotonin (5-HT₂), alpha-1 adrenergic, and histamine (H₁) receptors.
Slow-release formulation: Provides sustained antipsychotic effects for 4 weeks per dose.

Dosage & Administration

Initial Dose (for Stabilized Patients)

Only for patients already stabilized on lower doses (e.g., 200–300 mg monthly).
Max initial dose: 300 mg IM (400 mg is not for first-time depot users).

Maintenance Dose

200–400 mg IM every 4 weeks (reserved for severe cases with proven tolerance).

Administration

Deep IM injection (gluteal muscle preferred).
Never give IV or subcutaneously (risk of oil embolism).

Switching from Oral to Depot

Overlap oral haloperidol for 4–8 weeks to ensure stability before using 400 mg dose.

Indications

✅ Severe, treatment-resistant schizophrenia (non-adherent patients).
✅ Chronic psychotic disorders with high relapse risk.
❌ Not for acute psychosis or first-episode patients.

Storage & Stability

Store at 15–30°C, protect from light.
Do not freeze (oil base may solidify).
Stable for 3 months after first use if stored properly.

Key Recommendations

✔ Strictly monitor for EPS (high risk of dystonia, akathisia, tardive dyskinesia).
✔ Mandatory ECG monitoring (↑↑ QT prolongation risk at this dose).
✔ Avoid in elderly/dementia patients (↑ mortality – Black Box Warning).
✔ Titrate slowly (400 mg is only for patients tolerating 300 mg well).

Important Safety Notes

⚠ Black Box Warnings:

↑ Mortality in elderly dementia patients (not approved for dementia-related psychosis).
High risk of QT prolongation & torsades de pointes.

⚠ Contraindications:

Parkinson’s disease/Lewy body dementia (worsens motor symptoms).
Congenital long QT syndrome.
Severe hepatic impairment.

⚠ Pregnancy (Category C): Risk of neonatal EPS; avoid unless critical.

Adverse Effects

Common	Serious
– Severe EPS (dystonia, tremors)	– Neuroleptic malignant syndrome (NMS)
– Sedation	– Torsades de pointes
– Weight gain	– Irreversible tardive dyskinesia
– Hyperprolactinemia	– Seizures

Drug Interactions

Interacting Drug	Effect	Management
CYP3A4 inhibitors (ketoconazole)	↑↑ Haloperidol levels	Contraindicated
QT-prolonging drugs (amiodarone)	↑↑ Arrhythmia risk	Absolute avoid
CNS depressants (benzodiazepines)	↑↑ Sedation	Extreme caution

Comparison with Other High-Potency Depot Antipsychotics

Feature	HALD SR 400 mg	Fluphenazine Decanoate	Zuclopenthixol Decanoate
Dosing Interval	Every 4 weeks	Every 2–4 weeks	Every 2–4 weeks
EPS Risk	Very High	High	Moderate-High
QT Risk	Extreme	High	Moderate
Cost	Low	Low	Moderate

Conclusion

Shipping Options –

We offer a variety of shipping options, including Express Mail Service (EMS), USPS, DHL, FedEx, TNT, UPS, Aramex, Air Cargo, and sea freight.

Terms and Conditions –

Bulk Orders: You are responsible for any local import duties and taxes in your country.

For Patients: When ordering prescription medicines for personal use, or for a friend or relative, a valid medical practitioner’s script or prescription is required.

Return and Refund Policy: Due to the nature of our products, we cannot accept returns or exchanges once a purchase is made. However, in the event of non-delivery, you are eligible for either a 100% refund or a reshipment of your order.

Description
Reviews (0)

Composition

Active Ingredient: Haloperidol Decanoate 400 mg/mL (in sesame oil base).
Vehicle: Sesame oil, benzyl alcohol (preservative).

Mechanism of Action

Potent dopamine (D₂) receptor antagonist (primary action in mesolimbic pathway).
Also blocks serotonin (5-HT₂), alpha-1 adrenergic, and histamine (H₁) receptors.
Slow-release formulation: Provides sustained antipsychotic effects for 4 weeks per dose.

Dosage & Administration

Initial Dose (for Stabilized Patients)

Only for patients already stabilized on lower doses (e.g., 200–300 mg monthly).
Max initial dose: 300 mg IM (400 mg is not for first-time depot users).

Maintenance Dose

200–400 mg IM every 4 weeks (reserved for severe cases with proven tolerance).

Administration

Deep IM injection (gluteal muscle preferred).
Never give IV or subcutaneously (risk of oil embolism).

Switching from Oral to Depot

Overlap oral haloperidol for 4–8 weeks to ensure stability before using 400 mg dose.

Indications

✅ Severe, treatment-resistant schizophrenia (non-adherent patients).
✅ Chronic psychotic disorders with high relapse risk.
❌ Not for acute psychosis or first-episode patients.

Storage & Stability

Store at 15–30°C, protect from light.
Do not freeze (oil base may solidify).
Stable for 3 months after first use if stored properly.

Key Recommendations

✔ Strictly monitor for EPS (high risk of dystonia, akathisia, tardive dyskinesia).
✔ Mandatory ECG monitoring (↑↑ QT prolongation risk at this dose).
✔ Avoid in elderly/dementia patients (↑ mortality – Black Box Warning).
✔ Titrate slowly (400 mg is only for patients tolerating 300 mg well).

Important Safety Notes

⚠ Black Box Warnings:

↑ Mortality in elderly dementia patients (not approved for dementia-related psychosis).
High risk of QT prolongation & torsades de pointes.

⚠ Contraindications:

Parkinson’s disease/Lewy body dementia (worsens motor symptoms).
Congenital long QT syndrome.
Severe hepatic impairment.

⚠ Pregnancy (Category C): Risk of neonatal EPS; avoid unless critical.

Adverse Effects

Common	Serious
– Severe EPS (dystonia, tremors)	– Neuroleptic malignant syndrome (NMS)
– Sedation	– Torsades de pointes
– Weight gain	– Irreversible tardive dyskinesia
– Hyperprolactinemia	– Seizures

Drug Interactions

Interacting Drug	Effect	Management
CYP3A4 inhibitors (ketoconazole)	↑↑ Haloperidol levels	Contraindicated
QT-prolonging drugs (amiodarone)	↑↑ Arrhythmia risk	Absolute avoid
CNS depressants (benzodiazepines)	↑↑ Sedation	Extreme caution

Comparison with Other High-Potency Depot Antipsychotics

Feature	HALD SR 400 mg	Fluphenazine Decanoate	Zuclopenthixol Decanoate
Dosing Interval	Every 4 weeks	Every 2–4 weeks	Every 2–4 weeks
EPS Risk	Very High	High	Moderate-High
QT Risk	Extreme	High	Moderate
Cost	Low	Low	Moderate

Conclusion

Reviews

There are no reviews yet.

Be the first to review “HALD SR 400 MG”

Description
Reviews (0)

Composition

Active Ingredient: Haloperidol Decanoate 400 mg/mL (in sesame oil base).
Vehicle: Sesame oil, benzyl alcohol (preservative).

Mechanism of Action

Potent dopamine (D₂) receptor antagonist (primary action in mesolimbic pathway).
Also blocks serotonin (5-HT₂), alpha-1 adrenergic, and histamine (H₁) receptors.
Slow-release formulation: Provides sustained antipsychotic effects for 4 weeks per dose.

Dosage & Administration

Initial Dose (for Stabilized Patients)

Only for patients already stabilized on lower doses (e.g., 200–300 mg monthly).
Max initial dose: 300 mg IM (400 mg is not for first-time depot users).

Maintenance Dose

200–400 mg IM every 4 weeks (reserved for severe cases with proven tolerance).

Administration

Deep IM injection (gluteal muscle preferred).
Never give IV or subcutaneously (risk of oil embolism).

Switching from Oral to Depot

Overlap oral haloperidol for 4–8 weeks to ensure stability before using 400 mg dose.

Indications

✅ Severe, treatment-resistant schizophrenia (non-adherent patients).
✅ Chronic psychotic disorders with high relapse risk.
❌ Not for acute psychosis or first-episode patients.

Storage & Stability

Store at 15–30°C, protect from light.
Do not freeze (oil base may solidify).
Stable for 3 months after first use if stored properly.

Key Recommendations

✔ Strictly monitor for EPS (high risk of dystonia, akathisia, tardive dyskinesia).
✔ Mandatory ECG monitoring (↑↑ QT prolongation risk at this dose).
✔ Avoid in elderly/dementia patients (↑ mortality – Black Box Warning).
✔ Titrate slowly (400 mg is only for patients tolerating 300 mg well).

Important Safety Notes

⚠ Black Box Warnings:

↑ Mortality in elderly dementia patients (not approved for dementia-related psychosis).
High risk of QT prolongation & torsades de pointes.

⚠ Contraindications:

Parkinson’s disease/Lewy body dementia (worsens motor symptoms).
Congenital long QT syndrome.
Severe hepatic impairment.

⚠ Pregnancy (Category C): Risk of neonatal EPS; avoid unless critical.

Adverse Effects

Common	Serious
– Severe EPS (dystonia, tremors)	– Neuroleptic malignant syndrome (NMS)
– Sedation	– Torsades de pointes
– Weight gain	– Irreversible tardive dyskinesia
– Hyperprolactinemia	– Seizures

Drug Interactions

Interacting Drug	Effect	Management
CYP3A4 inhibitors (ketoconazole)	↑↑ Haloperidol levels	Contraindicated
QT-prolonging drugs (amiodarone)	↑↑ Arrhythmia risk	Absolute avoid
CNS depressants (benzodiazepines)	↑↑ Sedation	Extreme caution

Comparison with Other High-Potency Depot Antipsychotics

Feature	HALD SR 400 mg	Fluphenazine Decanoate	Zuclopenthixol Decanoate
Dosing Interval	Every 4 weeks	Every 2–4 weeks	Every 2–4 weeks
EPS Risk	Very High	High	Moderate-High
QT Risk	Extreme	High	Moderate
Cost	Low	Low	Moderate

Conclusion

Reviews

There are no reviews yet.

Be the first to review “HALD SR 400 MG”

Medical Disclaimer

Anteka Pharmacy primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on Anteka Pharmacy. Our mission is to support, not replace, the doctor-patient relationship.